The recent report of a working group, chaired by Professor Sir David Weatherall, on the use of nonhuman primates in research 1 has engendered little interest from doctors. This is regrettable because not only does the report address the scientific, moral and emotional issues, it presents views on research audit, medical ethics and public opinion, all of which are of direct concern to the profession.
The report was sponsored by the Academy of Medical Sciences, the Medical Research Council, the Royal Society and the Wellcome Trust. Its central goal was 'to examine the scientific case for the use of non-human primates for research into the prevention or treatment of disease, or for fundamental research that has the long-term potential of achieving the same end'. The working group's deliberations were informed by evidence from 31 organizations and 64 individuals, most of whom were academic scientists, and it paid particular attention to the fields of communicable disease and neuroscience. The report's findings were targeted at 'policy-makers in government, research funders, universities, scientific societies and relevant professional and regulatory bodies, as well as all other interested parties'. Its recommendations on sharing and publication of research findings, audit, development of alternatives and improving animal welfare will be perceived as well-founded, whereas its arguments for the scientific and moral justification of such research may be seen as contentious.
The scientific issues
The report concludes: 'There is a strong scientific case for the carefully regulated use of non-human primates, where there are no other means to address clearly defined questions of particular biological or medical importance'. This conclusion was not easily reached, the analysis having been 'extremely complex' and there are two caveats: + 'Unfortunately, while much of the material (on both sides of the argument) provides numerous examples of the value, or lack thereof, of animal research, very little of it explores these questions in the depth required to form a reasoned conclusion.' + 'It is undoubtedly the case that all animal models are limited in their predictability for humans.'
In its review of communicable disease research, the report focused on experimental work aimed at developing vaccines for HIV/AIDS, malaria and tuberculosis. The failure of candidate HIV vaccines to prove effective in humans was not seen by the working group as contraindicating further research, although the outlook is not good: according to a recent report, 2 leading HIV researcher Professor Robin Weiss 'has admitted he is pessimistic about the prospects of achieving an effective vaccine in the near future.' In the work on malaria, the report noted the challenging observation that a single attack of malaria 'offers very little protection against future attacks'. There was also the problem that 'many vaccines that are safe and highly immunogenic in mice have shown very little immunogenicity in humans and non-human primates.' Progress towards a vaccine for tuberculosis has also been disappointing; the report notes the problem of predicting human efficacy of vaccines developed in rodents because of immune system differences, but continues: 'Nevertheless, the major thrust of vaccine research using non-human primates is currently focused on trials of candidates that have shown protective effects in mice and guinea pigs.'
In neuroscience, the report's focus was on the use of non-human primates in the development and testing of drugs for Parkinson's disease, Alzheimer's disease and stroke. Reference was also made to deep brain stimulation and its success in controlling movement in patients with Parkinson's disease. Unfortunately, deep brain stimulation has no influence on disease progression and 'many problems remain in the management of Parkinson's disease'. Research on candidate drugs for stroke has not produced any effective treatments, and while some drugs provide symptomatic relief in Parkinson's disease and Alzheimer's disease, 'effective therapeutics still seem to be some way off'.
In the chapter on neuroscience, fundamental research is extensively reviewed, the report emphasizing: 'In this context, and as stressed elsewhere in this enquiry, we do not consider there to be a sharp distinction between research addressing fundamental scientific questions and work directed at more clinical problems'. Sir David Weatherall explained: 'The reason that we tried to get this concept over is simply that from the limited amount of data that are available on the public perception of animal research, there seems to be more concern about basic than medically driven science, but it really is a continuum.' 3
The moral issues
The working group 'accepted a moral case for careful, well-monitored and meticulously regulated non-human primate research, provided it is of a high quality and has the potential to benefit mankind, and if it is the only way of solving important scientific or medical questions'.
In arguing the case, three approaches were used: The hospital fire thought experiment
Here, the working group argues reasonably that, in a fire in a teaching hospital with an animal research laboratory, people would expect human beings to be saved before animals. However, the report then goes on: 'Humans think it is morally required to sacrifice the lives of animals to save human life (consistency then requires that they should do so -other things being equal -in medical research, as well as in hospital fires)'. These are not comparable scenarios: in the hospital fire, after the people are rescued, the hospital cat and the animals in the laboratory would, if possible, be saved; whereas, in medical research, it is intended that animals will be sacrificed. The philosopher Mary Midgley, in considering the comparable lifeboat model, offers a helpful analysis: 'I am suggesting that -contrary to the views of some egalitarians -those who use the lifeboat model are right to suppose that, in cases of real, sharp, life-or-death competition, we can indeed owe special, overriding duties based on kinship and other forms of social nearness. From a burning building, or even a milder disaster, we are right to rescue first our nearest and dearest. Theorists who deny this, exalting impartiality as the core of virtue, are muddled. And this is true of nearness in species as well as of other kinds. But it cannot possibly mean that those further from us are always too far down the queue to be reached'. 4
Comparison of harm to animals and humans
In this approach, the use of non-human primates is justified 'lest greater harm occur' in humans: 'This is an application of perhaps the most basic ethical and medical principle of "do the least harm possible"'. The problem here is with the working group's interpretation of medical ethics: the most basic ethical and medical principle is not 'do the least harm possible', but 'first do no harm', an unequivocal directive, which would preclude invasive animal experiments.
Comparison of numbers
Here the number of non-human primates used in an experiment was compared with the number of people who might benefit: 'So the equation to be made is not simply between suffering caused and benefits to humans: both sides must be multiplied by the number of individuals involved. In the case of AIDS research, for instance, the number of macaques used may be measured in dozens, the number of humans who stand to benefit could be measured in millions.' Such an argument could, however, be used to justify virtually all experiments, effectively excluding animals from any moral defence.
The emotional concerns
The working group noted: 'Several respondents highlighted that neuroscience is the field of nonhuman primate research that raises the most concerns about welfare.' The report describes an invasive technique for insertion of microelectrodes by means of a stainless steel cap, fixed earlier under anaesthesia, and the subsequent experiments. It was the view of researchers that, 'while these procedures might appear alarming, they are tolerated well by the animals'. Pictures of distressed animals undergoing such procedures are available on the internet, and I sought the views of the working group on one such image (from Journal of the Royal Society of Medicine www.aesop-project.org). Sir David Weatherall replied: 'I fully agree with you that the kind of image that you enclosed with your letter must harm the reputation of medicine as a caring profession, and, incidentally, tend to reduce public goodwill towards medical research'. 5
Discussion
The working group's deliberations did not benefit from any up-to-date audit or cost-benefit analysis of non-human primate research. Furthermore, failure to develop effective vaccines for HIV/AIDS, malaria and tuberculosis, or effective drugs for Parkinson's disease, Alzheimer's disease and stroke; and unreliability as a model for human disease and for assessing drug and vaccine safety all cast doubt on the relevance of such research for clinical practice. The report's conclusion that there is a strong scientific case is therefore unsafe, and its recommendation that 'the major funding organizations should undertake a systematic review of the outcome of all their research using non-human primates supported over the last decade' takes on particular significance. The inclusion of costbenefit analyses in such reviews would add authority.
On the moral side, there is a dilemma: animal researchers tend to take a utilitarian approach, whereas clinicians are guided by the principle of 'first do no harm'. Should this remain the case, or should 'do the least harm possible' be adopted as the basic principle? This would certainly allow clinical, applied and fundamental research to unite under the same guiding principle. On the other hand, would abandoning 'first do no harm' as the profession's guiding principle change public perception of the doctor-patient relationship and diminish the vocational status of the profession?
On the emotional side, concern arising from images of invasive neurological research could harm the profession's relationship with the public and reduce support for research. While attempts could be made to persuade the public that the animals portrayed tolerate these procedures well, this would probably be met with disbelief.
The need to debate these and other questions arising from the report is clear enough and the working group recognizes this: 'the only way forward is to obtain a consensus opinion of the acceptability, or otherwise, of animal research. This should be based on widespread, informed public debate.' There is, however, a stumbling block, namely the fact that the profession as a whole and its representative and regulatory bodies take little active interest in animal research. According to the British Medical Association's Dr Vivienne Nathanson, the BMA 'believes animal experimentation is necessary at present to develop a better understanding of diseases and how to treat them, but endorses the concept that wherever possible, alternative experimental methods should be used.' However, the BMA tends not to fund animal research, 'because the great majority of the grants awarded by the Board of Science are used for clinical studies involving patients.' 6 Sir Graeme Catto, President of the General Medical Council (GMC), advises in regard to animal research that the GMC 'does not attempt to set, nor require doctors to follow, separate standards from those required by law, or covered by statutory codes of practice'. 7 Perhaps most importantly, the profession itself, according to Professor Patrick Vallance, 'has discreetly distanced itself' from the debate (JRSM 2002;95:277). 8 If the working group's hope for widespread informed debate is to be realized, and if the profession is to be involved, the Academy of Medical Sciences and the other sponsors of the report may have to take the initiative.
Conclusion
The report's target audience, which consists largely of organizations and institutions supportive of animal research, will very likely endorse the document as the authoritative source of guidance for research development, notwithstanding its scientific and moral weaknesses. In the absence of debate, these weaknesses will not be recognized and addressed. The concern, then, would be for unnecessary animal suffering, misuse of research resources, erosion of medical ethics and decline of support for research. The wide-ranging debate recommended by the working group should therefore take place, but it will have authority only if the medical profession is involved.
